Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with Eculizumab

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2546-2553

  Noone, D ^a   Al Matrafi, J ^a   Tinckam, K ^b   Zipfel, P F ^c,d   Herzenberg, A M ^e   Thorner, P S ^a   Pluthero, F G ^a   Kahr, W H A ^a,f   Filler, G ^g   Hebert, D ^a   Harvey, E ^a   Licht, C ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HANS KNÖLL INSTITUTE   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Antibody mediated rejection; atypical hemolytic uremic syndrome; complement Factor H related protein 3 1; donor specific antibodies; eculizumab; kidney transplant; sensitization; thrombotic microangiopathy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN 3; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HLA B27 ANTIGEN; HLA DQ ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; CASE REPORT; COMPLEMENT DEFICIENCY; COMPLEMENT FACTOR H RELATED PROTEIN 3 DEFICIENCY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESENSITIZATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOLOGY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MICROANGIOPATHY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REFLUX NEPHROPATHY; SPINA BIFIDA; THROMBOCYTOPENIA;

ADOLESCENT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD PROTEINS; COMPLEMENT C3B INACTIVATOR PROTEINS; FEMALE; GRAFT REJECTION; HUMANS;

EID: 84865611225     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04124.x     Document Type: Article

References (33)

1. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK,. Antibody-mediated rejection in kidney transplantation: An update. Expert Opin Pharmacother 2011; 12: 579-592.
2. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
3. Higgins R, Zehnder D, Chen K, et al,. The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation. Nephrol Dial Transplant 2011; 25: 1306-1312.
4. Moake J,. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009; 22: 567-576.
5. Meehan SM, Kremer J, Ali FN, et al,. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol 2011; 6: 395-403.
6. Levine MH, Abt PL,. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol 2012; 24: 136-142.
7. Woodruff TM, Nandakumar KS, Tedesco F,. Inhibiting the C5-C5a receptor axis. Mol Immunol 2010; 48: 1631-1642.
8. Roth A, Duhrsen U,. Treatment of paroxysmal nocturnal Hemoglobinuria in the era of eculizumab. Eur J Haematol 2011; 87: 473-479.
9. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, et al,. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1316.
10. Locke JE, Magro CM, Singer AL, et al,. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
11. Stegall MD, Diwan T, Raghavaiah S, et al,. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
12. Heinen S, Hartmann A, Lauer N, et al,. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439-2447.
13. Zipfel PF, Edey M, Heinen S, et al,. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3: e41.
14. Jozsi M, Licht C, Strobel S, et al,. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514. (Pubitemid 351213440)
15. Dragon-Durey MA, Blanc C, Marliot F, et al,. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450.
16. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB,. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342-347.
17. Nankivell BJ, Alexander SI,. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-1462.
18. Webber A, Hirose R, Vincenti F,. Novel strategies in immunosuppression: Issues in perspective. Transplantation 2011; 91: 1057-1064.
19. Ponticelli C, Banfi G,. Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006; 19: 789-794. (Pubitemid 44358844)
20. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM,. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011; 92: e42-e43.
21. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A,. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report. Transplant Proc 2011; 43: 2097-2101.
22. Chen Song S, Zhong S, Xiang Y, et al,. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011; 11: 2057-2066.
23. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P,. The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-367. (Pubitemid 38639887)
24. Fritsche LG, Lauer N, Hartmann A, et al,. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet 2010; 19: 4694-4704.
25. Sissons JG, Liebowitch J, Amos N, Peters DK,. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J Clin Invest 1977; 59: 704-715. (Pubitemid 8073831)
26. Walport MJ,. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
27. Manuelian T, Hellwage J, Meri S, et al,. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-1190. (Pubitemid 36519935)
28. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS,. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009; 284: 15650-15658.
29. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al,. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712.
30. Zipfel PF, Mache C, Muller D, Licht C, Wigger M, Skerka C,. DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 2010; 25: 2009-2019.
31. Zhao J, Wu H, Khosravi M, et al,. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079.
32. Gharavi AG, Kiryluk K, Choi M, et al,. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
33. Le Quintrec M, Lionet A, Kamar N, et al,. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 1694-1701.